Background and aims: Our study aimed to establish safer methods to manage home blood transfusion by using a remote vital signs data monitoring system. Home care is administered for patients with various medical disorders; however, home blood transfusion remains challenging owing to the risk of transfusion‐related complications.Methods: We set up a remote vital signs data monitoring system to improve the safety of home blood transfusions. Using an Internet‐based vital signs data monitoring system, the heart rate, electrocardiography, respiration rate, and percutaneous oxygen saturation (SpO2) were monitored and recorded during the entire home transfusion period.Results: Ten transfusions in three patients were monitored; two of the patients had an abnormality in a single vital sign (decreased SpO2 decrease and increased respiratory rate); these were not transfusion‐related complications. Vital sign anomalies also occur because of errors in using the measurement device and noise associated with body movements. The presence of abnormalities in at least two vital signs among SpO2 decrease, tachycardia, and increased respiratory rate that persisted for >5 minutes was defined as a complicated vital sign abnormality (CVSA). There were no severe transfusion‐related complications with CVSA in the present study.Conclusion: This study indicates the feasibility and sustainability of real‐time remote monitoring of vital signs for the safety of home transfusion. Although CVSA may function as an indicator of severe transfusion‐related complications, these findings need to be confirmed with further studies.
Background: Although the prognosis of follicular lymphoma (FL) has improved, some patients experience early disease progression, including progression of disease within 24 months (POD24). Histological transformation is a critical event in FL. However, the heterogeneity of FL tumors makes it challenging to diagnose transformation accurately. We retrospectively applied the clinical transformation criteria used for FL transformation assessments at relapse or disease progression to conduct transformation assessments before the initial immunochemotherapy. Methods: Sixty-six FL patients who first received immunochemotherapy between January 2009 and February 2023 at our institution were selected. Twenty-three were clinical-transformation-positive (CLT+). Results: The progression-free survival (PFS) rate of the CLT+ patients was significantly lower than that of the clinical-transformation-negative (CLT−) patients. In the POD24 assessment subgroup, the CLT+ patients had a higher incidence of POD24 than the CLT− patients. There was no significant difference in PFS between the patients treated with CHOP-like regimens and those treated with bendamustine regimens. In the CHOP-like group, the CLT+ patients exhibited significantly lower PFS than the CLT− patients. In the bendamustine group, the clinical transformation did not affect PFS. Conclusion: Clinical transformation criteria may be useful for the prognostic stratification of FL prior to immunochemotherapy. Additionally, they may serve as predictors of POD24.
A 49-year-old female was admitted to our hospital with malaise and gross hematuria. As ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was absent and the ADAMTS13 inhibitor was detected, she was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). In addition to plasma exchange and corticosteroid therapy, she received rituximab therapy for inhibitor boosting but died suddenly of a cardiac arrest on day 9. The postmortem revealed microvascular platelet thrombi in multiple organs. In this case, the deterioration of the patient’s clinical status was considered to have been caused by inhibitor boosting-induced systemic microvascular occlusion. In particular, her sudden death may have been due to cardiovascular microthrombosis. Since inhibitor boosting can cause TTP patients to deteriorate rapidly, it is crucial to manage TTP patients who undergo inhibitor boosting appropriately. The monitoring of cardiac complications in TTP patients may also be essential, especially in the acute phase.
Background and Aims: Home blood transfusion is thought to be a promising solution for reducing the burden of hospital visits for elderly patients with hematologic diseases such as myelodysplastic syndrome and leukemia. However, safety concerns and reliance on nonprofessional attendants currently limit its widespread adoption in Japan. We evaluated feasibility (completion of scheduled measurement points per transfusion day) and operational safety (frequency of alerts and proportion leading to clinical actions) of intermittent vital sign monitoring with real‐time remote alerts during home blood transfusions in Japan. Methods: Five patients receiving home transfusions via Akasaka Clinic between December 2022 and February 2023 participated in the study. A digital tablet‐based system was preconfigured to connect with Bluetooth‐enabled vital sign devices (blood pressure monitor, thermometer, and pulse oximeter). Before transfusion, baseline vital signs were measured by the visiting physician; attendants then measured vitals at 15 and 60 min and at the end of transfusion. Data were automatically transmitted to physicians via the Heartline™ system. If preset thresholds were exceeded, alerts were triggered, which prompted professional medical intervention. Results: During the 30‐day trial period, red blood cell transfusions were performed 27 times (each consisting of 2 units), and platelet concentrate transfusions were performed 15 times (each consisting of 10 units). Measurement completion rates ranged from 38% to 94% (median 70% [IQR 53–88]). Alerts occurred on 12/30 days and totaled 12 alert events, corresponding to 28.6 alerts per 100 transfusions. Four of 12 alert events (33.3%) led to clinical actions (medication administration or initiation of home oxygen). Notably, intermittent measurement effectively identified clinically significant changes. Attendants, including elderly cohabitants, were able to operate the system with minimal burden. Conclusion: Intermittent, attendant‐performed vital sign monitoring with real‐time alerts enabled timely clinical responses and was feasible, even among elderly caregivers.